To hear about similar clinical trials, please enter your email below
Trial Title:
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID:
NCT05526443
Condition:
Pancreatic Cancer
Advanced Pancreatic Carcinoma
Conditions: Official terms:
Adenocarcinoma
Pancreatic Neoplasms
Antineoplastic Agents
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
all approved chemotherapeutic agents from second line
Description:
all approved chemotherapeutic agents from second line
Arm group label:
Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
Summary:
To systematically collect and analyse real-world data on treatment patterns, clinical
outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma
(PDAC) undergoing systematic treatment in Austria
Detailed description:
1000 adult patients with locally advanced inoperable and/or metastasized PDAC undergoing
first line chemotherapy
Criteria for eligibility:
Study pop:
1000 adult patients with locally advanced inoperable and/or metastasized PDAC undergoing
first line therapy with a platinum- or gemcitabin- based chemotherapy
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- 18 years, female and male
- ECOG (Eastern Cooperative Oncology Group) Scale 0-2
- Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic
PDAC
- Patients undergoing palliative 1st line chemotherapy
- Signed informed consent for prospective patients, for retrospective cases no
informed consent is required
Exclusion Criteria:
- Patients with locally advanced operable PDAC who do not receive palliative
chemotherapy
- Patients with locally advanced borderline resectable PDAC who do not receive
palliative chemotherapy
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Medical University Graz Department of Oncology
Address:
City:
Graz
Zip:
8036
Country:
Austria
Status:
Recruiting
Contact:
Last name:
Jakob Riedl, Dr. Dr.
Phone:
+43 316 385 31256
Email:
j.riedl@medunigraz.at
Contact backup:
Last name:
Karin Groller, MPH
Phone:
+43 316 385 14174
Email:
karin.groller@medunigraz.at
Investigator:
Last name:
Jakob Riedl, Dr. Dr.
Email:
Principal Investigator
Start date:
January 13, 2023
Completion date:
October 2025
Lead sponsor:
Agency:
Medical University of Graz
Agency class:
Other
Collaborator:
Agency:
Medical University of Vienna
Agency class:
Other
Collaborator:
Agency:
Medical University Innsbruck
Agency class:
Other
Collaborator:
Agency:
LKH Klagenfurt
Agency class:
Other
Collaborator:
Agency:
Krankenhaus Barmherzige Schwestern Linz
Agency class:
Other
Source:
Medical University of Graz
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05526443
